{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:41:09Z","timestamp":1776091269342,"version":"3.50.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>At present, the side effects of hormonal and immunosuppressant therapy for intermediate-to-high risk primary membranous nephropathy (PMN) are relatively large, and the remission rate is limited, so more safe and effective regimens are needed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study is a clinical prospective case series study. 31 patients were finally included. The intervention was cyclophosphamide (CTX) combined with \u201cShuli Fenxiao formula(SLFX formula)\u201d, and the patients were treated for 24 weeks. The observation nodes were baseline, 2 weeks\u300112weeks and 24weeks after treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At 12 weeks of treatment, 38.7% of patients achieved partial response. At 24 weeks of treatment, 61.3% of patients achieved partial response and 24.5% achieved complete response. All Anti-phosholipase A2 Receptor Antibody (Anti-PLA2R) seropositive patients achieved immune remission. 24-hour urine total protein quantification (24hUTP) decreased from a median of 6.1 (IQR, 4.6-8.4) g\/d to 2.7 (IQR, 0.6-8.7) g\/d (P&amp;lt;0.001). Serum albumin (ALB) increased from 27.2 \u00b1 6.4 g\/L to 31.9 \u00b1 8.0 (P&amp;lt;0.05). Within 24 weeks of follow-up after discharge, no patients relapsed. During the treatment follow-up period, 6 adverse events occurred in 31 patients, 1 patient developed heart failure during the treatment period, which was not considered to be clearly associated with treatment regimen or nephrotic syndrome (NS), 3 patients were infected, and 2 patients had liver impairment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The results suggest that the combination of CTX and SLFX formula dramatically decreased Anti-PLA2R titers and 24hUTP levels, increased ALB in short term. The combination was safe and had few adverse effects. It has the potential to be used as a potential option for the clinical treatment of intermediate-to-high risk PMN patients, particularly for elderly patients with contraindications to corticosteroid use or those with refractory disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>International Traditional Medicine Clinical Trial Registry<\/jats:title><jats:p><jats:uri>http:\/\/itmctr.ccebtcm.org.cn\/<\/jats:uri>, identifier ITMCTR2025000355.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1543581","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T12:35:30Z","timestamp":1745325330000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Low-dose cyclophosphamide combined with chinese herbal medicine Shuli Fenxiao formula for the treatment of intermediate-to-high risk primary membranous nephropathy"],"prefix":"10.3389","volume":"16","author":[{"given":"Yiran","family":"Du","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingnan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongjie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenjie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11761116","article-title":"Primary membranous nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016010093","article-title":"Long-term exposure to air pollution and increased risk of membranous nephropathy in China","volume":"27","author":"Xu","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.05.028","article-title":"Key points in managing PLA2R-associated membranous nephropathy","volume":"9","author":"Ramachandran","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1159\/000368588","article-title":"Anti-phospholipase A2 receptor antibodies and the pathogenesis of membranous nephropathy","volume":"128","author":"Ronco","year":"2014","journal-title":"Nephron Clin Pract"},{"key":"B5","doi-asserted-by":"publisher","first-page":"sfae129","DOI":"10.1093\/ckj\/sfae129","article-title":"Ten tips on immunosuppression in primary membranous nephropathy","volume":"17","author":"Trujillo","year":"2024","journal-title":"Clin Kidney J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"B7","doi-asserted-by":"publisher","first-page":"6109","DOI":"10.3390\/ijms22116109","article-title":"The mechanism of drug nephrotoxicity and the methods for preventing kidney damage","volume":"22","author":"Kwiatkowska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016091022","article-title":"Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy","volume":"28","author":"Van den Brand","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1286422","article-title":"Comparison of the efficacy of steroid-free versus classic steroid-containing regimens in primary membranous nephropathy","volume":"15","author":"Xing","year":"2024","journal-title":"Front Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad225","article-title":"Membranous nephropathy treatment standard","volume":"39","author":"Radhakrishnan","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"B11","doi-asserted-by":"publisher","first-page":"w14030","DOI":"10.4414\/smw.2014.14030","article-title":"Cyclophosphamide: As bad as its reputation? Long-term single centre experience of cyclophosphamide side effects in the treatment of systemic autoimmune diseases","volume":"144","author":"Dan","year":"2014","journal-title":"Swiss Med Wkly"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.675406","article-title":"Herbal medicine \u201cShulifenxiao\u201d Formula for nephrotic syndrome of refractory idiopathic membranous nephropathy","volume":"12","author":"Cui","year":"2021","journal-title":"Front Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3969\/j.issn.1009-587X.2021.01.004","article-title":"Study on the internal mechanism of Shuli Fenxiao formula regulating autohagy against podocyte damage caused by complement membrane attack complex","volume":"22","author":"Yue","year":"2021","journal-title":"CJITWN"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.95321","article-title":"A dynamic prediction model for renal progression in primary membranous nephropathy","volume":"21","author":"Liang","year":"2024","journal-title":"Int J Med Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ndt\/gfae153","article-title":"Treatment of membranous nephropathy: a novel approach","volume":"40","author":"Van de Logt","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"B16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1186\/s12882-024-03912-4","article-title":"Comparations of efficacy and safety of rituximab, calcineurin inhibitors and cyclophosphamide in primary membranous nephropathy: a single-center retrospective analysis","volume":"25","author":"Lu","year":"2024","journal-title":"BMC Nephrol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.760708","article-title":"The risk of severe infections following rituximab administration in patients with autoimmune kidney diseases: Austrian ABCDE registry analysis","volume":"12","author":"Odler","year":"2021","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4314\/ejhs.v28i6.5","article-title":"Toxic effects of different doses of cyclophosphamide on liver and kidney tissue in Swiss Albino mice: A histopathological study","volume":"28","author":"Bhat","year":"2018","journal-title":"Ethiop J Health Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1860","article-title":"Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation","volume":"101","author":"McDonald","year":"2003","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2018.12.018","article-title":"Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: Old drug with a new vision","volume":"218","author":"Iqubal","year":"2019","journal-title":"Life Sci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.2215\/CJN.08880813","article-title":"Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy","volume":"9","author":"Van den Brand","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.10.014","article-title":"The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy","volume":"99","author":"Fern\u00e1ndez-Ju\u00e1rez","year":"2021","journal-title":"Kidney Int"},{"key":"B23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1009-587X.2019.02.016","article-title":"Clinical observation of membranous nephropathy in the treatment of chronic kidney injury caused by calcineurin inhibitors","volume":"20","author":"Cui","year":"2019","journal-title":"CJITWN"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.17344\/acsi.2024.8748","article-title":"Phytochemical analysis and evaluation of the antioxidant, anti-inflammatory, hemolytic, and antibacterial effects of astragalus gombo (L.) leaves","volume":"71","author":"Tlili","year":"2024","journal-title":"Acta Chim Slov"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.3390\/molecules29122730","article-title":"Uncovering the chemical composition and biological potentials of Bupleurum lancifolium hornem. from Jordan","volume":"29","author":"Al-Bataineh","year":"2024","journal-title":"Molecules"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000038531","article-title":"Explore the mechanism of Astragalus membranaceus and Poria cocos drug pair in improving immunity based on network pharmacology","volume":"103","author":"Bai","year":"2024","journal-title":"Med (Baltimore)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000481635","article-title":"Membranous nephropathy: approaches to treatment","volume":"47","author":"Bomback","year":"2018","journal-title":"Am J Nephrol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.593288","article-title":"Autoantibodies in the diagnosis, monitoring, and treatment of membranous nephropathy","volume":"12","author":"Tesar","year":"2021","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020071091","article-title":"Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial","volume":"32","author":"Scolari","year":"2021","journal-title":"JASN"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000422","article-title":"Combined serologic and genetic risk score and prognostication of PLA2R-associated membranous nephropathy","volume":"19","author":"Hu","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1053\/j.ajkd.2021.04.014","article-title":"Combination of rituximab, low-dose cyclophosphamide, and prednisone for primary membranous nephropathy: A case series with extended follow up","volume":"78","author":"Zonozi","year":"2021","journal-title":"Am J Kidney Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1543581\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T12:35:33Z","timestamp":1745325333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1543581\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2025.1543581"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1543581","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"article-number":"1543581"}}